US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In the fourth quarter, revenues dropped 7% year-on-year (YOY) to USD 3.515 billion. However, the Greater China region generated USD 522 million in sales after a 2% expansion. For the whole year, company revenues stood at USD 14.693 billion, down 3% YOY. Notably, the Greater China region saw its sales increase by 2% YOY to USD 2.167 billion, making it the only region with growth.
Sales Breakdown
During 2024, sales of Brands and Generics slid 4% and 1% YOY to USD 9.2 billion and USD 5.5 billion, respectively. The company reported a net loss of USD 634 million, compared with a net profit of USD 54.7 million in the same period last year.
Outlook for 2025
Viatris expects global sales in the range of USD 13.5 to USD 14 billion in 2025, with new product sales estimated at USD 450 million to USD 550 million.-Fineline Info & Tech
Leave a Reply